STAR SIGN study: Evaluation of COVID-19 vaccine efficacy against the SARS-CoV-2 variants BQ.1.1 and XBB.1.5 in patients with inflammatory bowel disease.

Simon WoelfelJoel DütschlerMarius KönigAlex DulovicNicole GrafDaniel JunkerVasileios OikonomouClaudia KriegerSamuel TrunigerAnnett FrankeAnnika EckholdKristina ForschSeraina KollerJacqueline WyssNiklas KrupkaMelanie OberholzerNicola FreiNora GeisslerPeter Schaubnull nullWerner C AlbrichMatthias FriedrichNicole Schneiderhan-MarraBenjamin MisselwitzWolfgang KorteJustus J BürgiStephan Brand

Published in: Alimentary pharmacology & therapeutics (2023)

Patients with IBD who are treated with anti-TNF biologics show impaired neutralisation against novel omicron sublineages BQ.1.1 and XBB.1.5 and may benefit from prioritisation for future variant-adapted vaccines.

Keyphrases

sars cov
patients with inflammatory bowel disease
coronavirus disease
respiratory syndrome coronavirus
rheumatoid arthritis
copy number
current status
gene expression
dna methylation
ulcerative colitis